NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to develop age-reversing treatments

NewLimit has raised $130 million in Series B funding, including Kleiner Perkins, Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and returning backers. Founded by Coinbase CEO Brian Armstrong and stem cell professor Jacob Kimmel, the company has made significant progress in reprogramming liver cells with three prototype medicines that restore youthful characteristics. While promising early results are encouraging, NewLimit remains focused on advancing anti-aging medicine through AI-driven simulations before transitioning to human trials.